MAP3K9 and pancreatic neoplasm: Interestingly, previous studies reported that miR-1247 targeting neuroplilin 1 and neuroplilin 2 in pancreatic cancer, targeting MAP3K9 in osteosarcoma, and targeting STMN1 in NSCLC, thereby regulated tumor cells proliferation.